Share Market Newspaper

MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now

 Breaking News
  • No posts were found

MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now

August 20
16:36 2026
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now

August 20, 2026 Micro-cap stocks across biotechnology, neurodegenerative disease, quantum computing and artificial intelligence are drawing investor attention as fresh corporate developments create potential catalysts. IGC Pharma, Inc. (NYSE: IGC), BioVie Inc. (NASDAQ: BIVI), QTREX Quantum Ltd. (NASDAQ: QTEX) Eightco Holdings Inc. (NASDAQ: ORBS) and Algorhythm Holdings, Inc. (NASDAQ: RIME) are among the emerging names investors are watching as clinical milestones, quantum technology advances and AI-linked investments come into focus.

IGC Pharma (NYSE: IGC) Approaches Key Alzheimer’s Phase 2 Readout

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, is approaching a potentially significant catalyst as its lead drug candidate, IGC-AD1, advances toward expected Phase 2 CALMA topline results in the fourth quarter of 2026.

The company recently strengthened its regulatory, biostatistical, pharmaceutical-development and AI-enabled data science capabilities as the CALMA study approaches completion. IGC reported that 160 participants had been randomized as of August 11, with enrollment expected to close following up to eight additional randomizations before follow-up, database lock, unblinding and topline analysis.

The approaching Q4 clinical readout puts IGC Pharma (NYSE American: IGC) in focus as investors continue searching for emerging Alzheimer’s and neurodegenerative disease opportunities.

BioVie (NASDAQ: BIVI) Reports Positive Phase 2 Parkinson’s Results

BioVie Inc. (NASDAQ: BIVI) recently reported topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage Parkinson’s disease, providing another potential catalyst within the neurodegenerative disease sector.

According to the company, patients treated with bezisterim demonstrated statistically significant improvements compared with placebo across motor and non-motor measures. BioVie also reported favorable changes in biomarkers associated with neurodegeneration and inflammation, while 283 of 380 proteins evaluated shifted in a direction the company said may be consistent with slowing disease progression. The study was designed in part to help inform development of a potentially pivotal Phase 3 trial.

The results put BioVie (NASDAQ: BIVI) on the radar as the company works to advance a differentiated therapeutic approach aimed at the underlying biology of Parkinson’s disease.

QTREX Quantum (NASDAQ: QTEX) Targets Major Quantum Computing Bottleneck

QTREX Quantum Ltd. (NASDAQ: QTEX), formerly Inspira Technologies, has repositioned itself around Additively Manufactured Electronics (AME) and quantum connectivity infrastructure. The company is targeting critical hardware challenges associated with scaling quantum computers, including heat, electromagnetic interference, connectivity and packaging inside cryogenic environments.

QTREX recently disclosed technology that uses localized laser processing to convert portions of 3D-printed dielectric material into conductive, graphene-like carbon structures. The approach is being developed for integration into quantum packages, with the goal of absorbing stray photons before they interfere with sensitive superconducting circuits.

The company continues to expand its quantum infrastructure strategy, including U.S. government initiatives, commercial manufacturing activity and research programs aimed at next-generation cryogenic interconnects. As quantum systems move toward higher qubit counts, QTREX Quantum (NASDAQ: QTEX) is positioning its AME platform as an enabling technology for increasingly complex quantum hardware.

Eightco Holdings (NASDAQ: ORBS) Reports Approximately $378 Million in Holdings

Eightco Holdings Inc. (NASDAQ: ORBS) has emerged as an unusual micro-cap vehicle providing exposure to several high-profile technology and digital-asset themes.

As of August 5, 2026, Eightco reported approximately $378 million in total holdings, including a $90 million indirect investment in OpenAI through special-purpose vehicles, an $18 million investment in Beast Industries, approximately 301.97 million WLD tokens, 16,278 ETH, and approximately $142 million in cash and stablecoins.

The portfolio gives Eightco Holdings (NASDAQ: ORBS) exposure to three major technology themes: artificial intelligence through OpenAI, digital identity through World/WLD, and the creator economy through Beast Industries. The company also recently participated in the World Foundation’s $52.5 million funding round.

Algorhythm (NASDAQ: RIME) Eyes AI Data Center Energy Expansion

Algorhythm Holdings, Inc. (NASDAQ: RIME) is drawing increased investor attention following elevated trading activity and improving operating results, with Q2 2026 revenue reaching approximately $3.0 million, up 25% sequentially and 161% year-over-year, alongside an EPS result that beat expectations, improved gross margin percentage, approximately $8.0 million in cash and restricted cash, and total assets of $18.6 million.

The Company’s SemiCab AI-powered logistics platform continues expanding with major enterprise customers including Coca-Cola India, Procter & Gamble India, Unilever India, Apollo Tyres and Onida Electronics, while SemiCab Apex targets additional growth in North America.

Additionally, Algorhythm is evaluating a business combination with an energy infrastructure company focused on power generation for data centers, potentially expanding RIME’s exposure into the growing AI, data center and energy infrastructure markets.

MicroCap Watch: IGC, BIVI, QTEX, ORBS

Together, IGC Pharma (NYSE: IGC), BioVie (NASDAQ: BIVI), QTREX Quantum (NASDAQ: QTEX), Eightco Holdings (NASDAQ: ORBS) and Algorhythm Holdings, Inc. (NASDAQ: RIME) provide exposure to four closely watched growth themes: Alzheimer’s therapeutics, Parkinson’s disease, quantum computing infrastructure and artificial intelligence/digital assets.

For speculative micro-cap investors, upcoming clinical milestones at IGC and BIVI, continued quantum technology development at QTEX and Eightco’s unusual portfolio of AI, digital identity and creator-economy assets give each company a distinct catalyst profile to watch.

About the Companies

IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company developing therapeutics and AI-enabled approaches targeting Alzheimer’s disease and related neurological conditions.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biotechnology company developing drug therapies targeting neurological, neurodegenerative and related diseases.

QTREX Quantum Ltd. (NASDAQ: QTEX) develops Additively Manufactured Electronics technology targeting quantum connectivity, cryogenic infrastructure and other advanced electronics applications.

Eightco Holdings Inc. (NASDAQ: ORBS) maintains a treasury and strategic investment strategy providing exposure to artificial intelligence, digital identity, digital assets and the creator economy.

Algorhythm Holdings, Inc. (NASDAQ: RIME) is an AI technology company focused on SemiCab, its AI-powered logistics platform designed to optimize freight networks, reduce empty truck miles, lower transportation costs and improve efficiency for shippers and carriers globally.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com